In adults with overweight or obesity who used weight-inducing medications in SURMOUNT-1, tirzepatide changed weight by -13.3% (5 mg) to -21.3% (15 mg) versus placebo at 72 weeks.
In plain wordsIn adults with obesity who also took weight-raising drugs, tirzepatide lowered weight more than placebo over 72 weeks, by 13.3% to 21.3%.
- Peptide
- Tirzepatide
- Outcome
- DecreaseWeight change at week 72 in SURMOUNT-1 with weight-inducing medications
- Study
n = 442
- Comparator
- Placebo
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- 5 mg to 15 mg · 72 weeksAs given in this study (human).
Measurements
- weight change vs placebo
- −13.3%
- tirzepatide 5 mg, SURMOUNT-1
- weight change vs placebo
- −21.3%
- tirzepatide 15 mg, SURMOUNT-1
Source sentences
The mean percentage weight change compared with placebo from randomization to 72 weeks for those treated with tirzepatide and using WI medication was -13.3% (95% CI, -16.0% to -10.7%) for 5 mg to -21.3% (95% CI, -23.9% to -18.7%) for 15 mg in SURMOUNT-1
1 context sentence(design, population, supporting numbers)
This post hoc analysis of the phase 3 randomized clinical trials SURMOUNT-1 (December 4, 2019, to April 1, 2022), SURMOUNT-3 (March 29, 2021, to May 12, 2023), and SURMOUNT-4 (March 29, 2021, to May 18, 2023) assessed the association between tirzepatide and weight reduction among participants taking…